Patients with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutations initially respond to EGFR-tyrosine kinase inhibitors (TKI) but eventually experience relapse. Acquired resistance to EGFR-TKIs is strongly associated with patient mortality. Thus, elucidation of the mechanism of acquired resistance to EGFR-TKIs is of great importance. In this study, gefitinib-resistant cell line models were established by long-term exposure to gefitinib using the gefitinib-sensitive lung cancer cell lines, PC9 and HCC827. Expression analyses indicated that both FGFR1 and FGF2 were increased in PC9 gefitinib-resistant (PC9 GR) cells as compared with PC9 naïve (PC9 na) cells. Importantly, proliferation of gefitinib-...
One of the most important pathways in non-small cell lung cancer (NSCLC) is the epidermal growth fac...
Different cell-signalling pathways have been successfully targeted in various hematologic and solid ...
In recent years, cancer treatments have progressed substantially. However, the tumor microenvironmen...
Despite initial and sometimes dramatic responses of specific NSCLC tumors to EGFR TKIs, nearly all w...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Lung adenocarcinoma cells harboring epidermal growth factor receptor (EGFR) mutations are sensitive ...
Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating mutations within t...
<div><p>Gefitinib and erlotinib are epidermal growth factor receptor-tyrosine kinase inhibitors (EGF...
Non-small cell lung carcinoma patients with epidermal growth factor receptor (EGFR) mutations are of...
AbstractSince the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth fa...
Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improves the ...
The discovery of several molecular alterations that underlie non-small cell lung cancer (NSCLC) path...
One of the most important pathways in non-small cell lung cancer (NSCLC) is the epidermal growth fac...
Different cell-signalling pathways have been successfully targeted in various hematologic and solid ...
In recent years, cancer treatments have progressed substantially. However, the tumor microenvironmen...
Despite initial and sometimes dramatic responses of specific NSCLC tumors to EGFR TKIs, nearly all w...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-s...
Lung adenocarcinoma cells harboring epidermal growth factor receptor (EGFR) mutations are sensitive ...
Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating mutations within t...
<div><p>Gefitinib and erlotinib are epidermal growth factor receptor-tyrosine kinase inhibitors (EGF...
Non-small cell lung carcinoma patients with epidermal growth factor receptor (EGFR) mutations are of...
AbstractSince the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth fa...
Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improves the ...
The discovery of several molecular alterations that underlie non-small cell lung cancer (NSCLC) path...
One of the most important pathways in non-small cell lung cancer (NSCLC) is the epidermal growth fac...
Different cell-signalling pathways have been successfully targeted in various hematologic and solid ...
In recent years, cancer treatments have progressed substantially. However, the tumor microenvironmen...